SEC Comment Letter for Neurogene Inc. (NGNE) (CIK 0001404644) (NGNE) — Jan 17, 2017
Neurogene Inc. (NGNE) (CIK 0001404644)
Date: Jan. 17, 2017 · CIK: 0001404644 · Accession: 0000000000-17-001578
AI Filing Summary & Sentiment
File numbers found in text: 333-215457
Letter
Mail Stop 4546 January 13, 2017 David J. Main President and Chief Executive Officer Aquinox Pharmaceuticals, Inc. 450-887 Great Northern Way Vancouver, B.C., Canada V5T 4T5
Re: Aquinox Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 6, 2017 File No. 333-215457
Dear Mr. Main :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at (202) 551 -2544 with any questions.
Sincerely,
/s/ Joseph McCann for
Show Raw Text
Mail Stop 4546 January 13, 2017 David J. Main President and Chief Executive Officer Aquinox Pharmaceuticals, Inc. 450-887 Great Northern Way Vancouver, B.C., Canada V5T 4T5 Re: Aquinox Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 6, 2017 File No. 333-215457 Dear Mr. Main : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551 -2544 with any questions. Sincerely, /s/ Joseph McCann for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Michael E. Tenta, Esq. Cooley LLP